Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Byrd

MOHS-Micrographic Surgery Rochester Hills, MI Medical Doctor

NPI 1467469197 CMS profile 292882

405 Barclay Cir, Rochester Hills, MI 48307

Open in the dashboard

General payments

$9,591

534 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Byrd of Rochester Hills, MI is reported in the CMS Open Payments database as having received $9,591 across 534 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,843 95
2024 General $1,984 91
2023 General $1,642 88
2022 General $1,541 86
2021 General $1,266 83
2020 General $733 46
2019 General $583 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Byrd
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to David Byrd were reported at $1,843. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year David Byrd MOHS-Micrographic Surgery median Middle half National median
2019 $583 $316 $106–$785 $163
2020 $733 $162 $68–$412 $114
2021 $1,266 $243 $87–$654 $132
2022 $1,541 $300 $102–$887 $149
2023 $1,642 $364 $125–$1,010 $160
2024 $1,984 $445 $142–$1,108 $164
2025 $1,843 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,322 75 payments
  2. AbbVie, Inc. $1,169 82 payments
  3. Novartis Pharmaceuticals Corporation $970 68 payments
  4. Galderma Laboratories, L.P. $820 34 payments
  5. LEO Pharma Inc. $811 68 payments
  6. Regeneron Healthcare Solutions, Inc. $661 28 payments
  7. Genzyme Corporation $588 24 payments
  8. Lilly USA, LLC $303 17 payments
  9. Pfizer Inc. $288 16 payments
  10. Ortho Dermatologics, a division of Bausch Health US, LLC $284 16 payments
  11. Other $2,376 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,118 528 payments
  2. Education $473 6 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $895 45 payments
  2. DUPIXENT Immunology $881 36 payments
  3. ADBRY $619 50 payments
  4. STELARA $509 39 payments
  5. DUPIXENT Inflammation And Immunology $506 22 payments
  6. COSENTYX Immunology $483 38 payments
  7. RINVOQ $470 38 payments
  8. COSENTYX Dermatology $461 27 payments
  9. SKYRIZI $429 31 payments
  10. SIMPONI ARIA $427 30 payments
  11. Other $6,689 369 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,237

Median for Dermatology: 534

Drug cost

$93,989

Median for Dermatology: $67,151

Branded share of claims

4.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $82,933
Cephalexin Generic 704 $2,931
Doxycycline Hyclate Generic 57 $1,507
Fluorouracil Generic 14 $897
Ketoconazole Generic 62 $805
Triamcinolone Acetonide Generic 65 $755
Betamethasone Dipropionate Generic 13 $664
Clindamycin Hcl Generic 111 $633
Ciclopirox Generic 20 $603
Valacyclovir Valacyclovir Hcl Brand 17 $529

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$910,159

Of which drugs: $2,789

Medicare patients

1,046

Average age 77

Services billed

8,068

394 women, 652 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 43%
Ischemic heart disease 37%
Diabetes 24%
Atrial fibrillation 22%
Chronic kidney disease 20%
Cancer 18%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 821 $83

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $251
  • GENZYME CORPORATION $154
$405 — —
ADBRY
  • LEO Pharma Inc. $182
$182 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $153
$153 11 —
VTAMA
  • Dermavant Sciences, Inc. $131
$131 — —
SKYRIZI
  • AbbVie, Inc. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record